[14] The latter is particularly relevant, since bladder cancer is the second most prevalent malignancy after prostate cancer in middle-aged and elderly men ... patients with advanced TCC and ...

Advanced transitional-cell carcinoma of the bladder is the most common cancer of the urinary tract, with a high mortality rate. Cisplatin-based chemotherapy has demonstrated prolonged survival of ...

Historically, chemotherapy using cisplatin has been the standard treatment for advanced bladder ... is the fourth most common among men. Like any other cancer, bladder cancer can spread beyond ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

Padcev plus Keytruda's approval as a first-line treatment for advanced bladder cancer may influence treatment options for platinum-ineligible patients. Initial Keytruda showed consistent antitumor ...

Prostate cancer is a malignant tumor that develops in the prostate gland, a part of the male reproductive system.

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer ...

Sir Chris Hoy, six-time Olympic cycling champion, has revealed he has advanced ... Prostate cancer that's detected early has the best chance for successful treatment. One in eight men will get ...

Bladder cancer occurs almost four times more frequently in men than in women. Between 15 and 25 percent of cases of this ...

Men who undergo prostate cancer treatment face a greatly increased risk of life-altering, long-term complications, a new study finds. Surgery for prostate cancers increases a man's risk of urinary ...